1.
Bioorg Med Chem Lett
; 19(19): 5552-5, 2009 Oct 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19720528
RESUMO
A 5-fluoro-tetrahydrocarbazole serotonin reuptake inhibitor (SRI) building block was combined with a variety of linkers and dopamine D2 receptor ligands in an attempt to identify potent D2 partial agonist/SRI molecules for treatment of schizophrenia. This approach has the potential to treat a broader range of symptoms compared to existing therapies. Selected compounds in this series demonstrate high affinity for both targets and D2 partial agonism in cell-based and in vivo assays.